Neurodegenerative diseases are one of the leading causes of death, disability and dependency worldwide. Since the etiology of these complex pathologies is not completely known, the available therapeutic options can only cause temporary relief of the symptoms, but cannot cure them. Life-changing therapeutic solutions are urgently needed, as the number of people suffering from these pathologies has been increasing quickly over the last few decades. Recent studies regarding the paradigm of using multitarget compounds to treat both Alzheimer's and Parkinson's diseases have been analyzed and included in the review entitled "Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?". This interview is based on this previously published overview, highlighting some of the most important aspects.
Keywords: Alzheimer's disease; Parkinson's disease; interview; molecular hybridization; multitarget drugs; small molecules.